All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Lenvanamo 4mg Tablet
Prescription Required
Salt Composition : Lenvatinib
Manufacturer : SHIVNAAM TRADELINK LLP
Origin of Medicine : India
30 Tablet(s) In A Bottle
Introduction to Lenvanamo 4mg Tablet
Lenvanamo 4mg Tablet is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment.
Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenvanamo 4mg Tablet or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenvanamo 4mg Tablet, as it can impair wound healing and increase the risk of bleeding.
Uses of Lenvanamo 4mg Tablet
Lenvanamo 4mg Tablet is indicated to treat the following conditions:
- Certain types of advanced thyroid cancer
- Advanced Liver cancer
- Certain types of kidney cancer
- Endometrial cancer
Therapeutic Effects of Lenvanamo 4mg Tablet
Lenvanamo 4mg Tablet blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumour cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.
Interaction of Lenvanamo 4mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Lenvanamo 4mg Tablet and reduce effectiveness by causing undesirable side effects.
More Information about Lenvanamo 4mg Tablet
- Lenvanamo 4mg Tablet should be stored at room temperature, between 20°C to 25°C (68°F to 77°F).
- Protected from light.
- Keep it in its original packaging until it is ready to be used.
- Keep out of the reach of children and pets.
- It should be disposed of properly.
How to consume Lenvanamo 4mg Tablet
Lenvanamo 4mg Tablet is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up for the second dose.
Safety Advices for Lenvanamo 4mg Tablet
Pregnancy
Lenvanamo 4mg Tablet is unsafe during pregnancy as it can cause fetal harm. It is s recommended to avoid this medication during pregnancy.
Breast Feeding
Breastfeeding is not recommended while taking Lenvanamo 4mg Tablet, as it can potentially harm the nursing infant.
Lungs
Lenvanamo 4mg Tablet can cause side effects that affect the lungs, such as cough, shortness of breath, and difficulty breathing. If a person experiences any of these symptoms while taking it, they should notify their healthcare provider right away.
Liver
Lenvanamo 4mg Tablet is primarily metabolized in the liver, so inform your healthcare provider if you have any liver problems or diseases. This medication may also increase liver enzymes, which can be a sign of liver damage or inflammation. Patients taking this medication require regular blood tests to monitor liver function monitored.
Alcohol
It is recommended to avoid consuming alcohol while taking Lenvanamo 4mg Tablet, as alcohol can increase the risk of certain side effects associated with the medication, such as stomach ulcers or gastrointestinal bleeding.
Driving
Patients receiving Lenvanamo 4mg Tablet should be advised to avoid driving or operating machinery if they experience side effects such as fatigue, dizziness, or blurred vision, impairing a patient's ability to drive or operate machinery safely.
Side Effects of Lenvanamo 4mg Tablet
Like all medications, Lenvanamo 4mg Tablet can cause side effects, although not everyone who takes it will experience them.
Serious:
- Feeling numb or weak on 1 side of the body
- Severe headache
- Fever
- Confusion
- Difficulty speaking
- Vision changes
- Dizziness
- Chest pain or pressure
- Pain in arms, jaw, neck, back
- Breathing problems
- Severe stomach pain
- Blood clot formation
- Blood in stools or coughing blood
- Liver problems
- Pain or soreness in mouth, teeth or jaw
Common:
- High or low BP
- Loss of appetite
- Nausea, vomiting, constipation, diarrhea or indigestion
- Tiredness
- Hoarse voice
- Leg swelling
- Rashes
- Pain in joints or muscles
- Hair loss
- Sleeplessness
- Protein in urine, frequent urination
- Low potassium, magnesium and calcium levels in the blood
- Dehydration
- Skin problems
- Gall bladder inflammation
- Increase in the values of cholesterol, thyroid-stimulating hormone, digestive enzymes
- Delayed wound healing
Word of Advice
If you are receiving close communication with your healthcare provider, report any concerns or side effects as soon as possible. Avoid getting pregnant and breastfeeding during treatment. Patients should use effective contraception while taking Lenvanamo 4mg Tablet and for at least two weeks after stopping treatment. Patients should avoid eating grapefruits as they affect the absorption of this drug. Patients should use sunscreen and wear protective clothing while outdoors to reduce the risk of sunburn or skin damage. You should avoid strenuous activities or exercise until you know how this medication is affecting you. Maintain a healthy and balanced diet during treatment to support your overall health and well-being. By being informed and engaged in your treatment, you can help ensure the best possible outcomes and manage any associated potential risks or complications.
FAQs
Q 1. Can Lenvanamo 4mg Tablet cause infertility?
Lenvanamo 4mg Tablet can cause changes in menstrual periods and may affect fertility in some women. Patients should discuss their fertility concerns with their healthcare provider before starting this medication.
Q 2. Can Lenvanamo 4mg Tablet cause hair loss?
Yes, hair loss is a potential side effect of Lenvanamo 4mg Tablet. However, not all patients experience hair loss while taking this medication. Patients should discuss the potential side effects with their healthcare provider before starting treatment.
Q 3. Can I go for teeth extraction if I am taking Lenvanamo 4mg Tablet?
Before undergoing any dental procedures, it's important to inform your dentist and healthcare provider that you are taking Lenvanamo 4mg Tablet. It can increase the risk of bleeding, and dental procedures that involve cutting or removing tissue may increase this risk further. Your healthcare provider and dentist may recommend taking certain precautions, such as temporarily stopping of this medication before the procedure or adjusting your medication dose.
Q 4. Can Lenvanamo 4mg Tablet cause vision problems?
Yes, vision problems are a potential side effect of Lenvanamo 4mg Tablet. Patients should report any changes in vision to their healthcare provider immediately.
Fact Box of Lenvanamo 4mg Tablet
Molecule name: Lenvatinib | Therapeutic class: Anticancer
|
Pharmacological class: Tyrosine kinase inhibitor | Indications: 1. Certain types of advanced thyroid cancer 2. Advanced Liver cancer 3. Endometrial cancer |
References
- Eisai Europe Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 20th April 2023], https://www.medicines.org.uk/emc/files/pil.6840.pdf
- Suyama and Iwase, Lenvatinib: A promising molecular targeted agent for multiple cancers, Cancer Control, 2018, 25, 1-5, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056795/pdf/10/1177 1073274818789361.pdf
- Q.M. Anstee, D.E.J. Jones, Liver and Biliary Tract Disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 921-988.
- M.W.J. Strachan, J. Newell-Price, Endocrine disease, Davidson’s Principles & Practice of Medicine, 22nd Edition, 2014, 733-796.
- Eisai Inc U.S Food and Safety Drug Administration (FDA) [Last revised Aug 2018], [Accessed on 20th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
